A review of the novel tissue factor antibody–drug conjugate: Tisotumab vedotin

Abstract

Objective

To review and compare the pharmacology, efficacy, and safety of the novel tissue factor antibody–drug conjugate, tisotumab vedotin

Data sources

Literature search was performed through PubMed MEDLINE, Google Scholar, ClinicalTrials.gov, and the Food and Drug Administration.

Data summary

Tisotumab vedotin, a novel tissue factor antibody–drug conjugate, was granted accelerated approval by the US FDA on 20 September 2021 for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin demonstrated clinical efficacy in a number of solid tumors in innovaTV 201 and more specifically in cervical cancer in the pivotal phase 2 innovaTV 204. In the single-arm innovaTV 204 study, 101 patients with recurrent or metastatic cervical cancer received intravenous tisotumab vedotin at the recommended dose of 2 mg/kg every 3 weeks until disease progression or unacceptable toxicity. The independent review committee confirmed an objective response rate of 24% with 7% complete responses and 17% partial responses. Tisotumab vedotin is associated with several notable adverse events with data from innovaTV 204 including ocular toxicity, hemorrhage, and peripheral neuropathy. Ninety-two percent of patients experienced treatment-related adverse events with 28% experiencing an adverse event of grade 3 or higher.

Conclusions

Metastatic cervical cancer has a high risk of relapse with few effective second-line therapeutic options. Current guidelines recommend single agent tisotumab vedotin as a possible option. Ongoing trials will further define its place in therapy.

Keywords

Lisotumab vedotin antibody–drug conjugate tissue factor vedotin monomethyl auristatin E cervical cancer recurrent/metastatic cervical cancer mechanism of action pharmacokinetics

Get full access to this article

View all access options for this article.

References

Cohen

Jhingran

Oaknin

, et al. Cervical cancer. Lancet 2019; 393: 169–182.

Sung

Ferlay

Siegel

, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.

Cancer Stat Facts: Cervical Cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/cervix.html (accessed on November 15, 2021).

Cervical Cancer. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. 2021. Version 1.2022 (accessed on November 15, 2021).

Coleman

Lorusso

Gennigens

, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021; 22: 609–619.

Monk

Sill

Burger

, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009; 27: 1069–1074.

Alberts

Blessing

Landrum

, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol 2012; 127: 451–455.

Garcia

Blessing

Vaccarello

, et al. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix. Am J Clin Oncol 2007; 30: 428–431.

Look

Blessing

Gallup

, et al. A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Am J Clin Oncol 1996; 19: 439–441.

10.

Schilder

Blessing

Morgan

, et al. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Gynecol Oncol 2000; 76: 204–207.

11.

Sutton

Blessing

DiSaia

, et al. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 1993; 49: 48–50.

12.

Verschraegen

Levy

Kudelka

, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997; 15: 625–631.

13.

Miller

Blessing

Bodurka

, et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the gynecologic oncology group. Gynecol Oncol 2008; 110: 65–70.

14.

Bookman

Blessing

Hanjani

, et al. Topotecan in squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Gynecol Oncol 2000; 77: 446–449.

15.

Muggia

Blessing

Method

, et al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2004; 92: 639–643.

16.

Chung

Ros

Delord

, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2019; 37: 1470–1478.

17.

De Bono

Concin

Hong

, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial. Lancet Oncol 2019; 20: 383–393.

18.

Breji

de Goeji

Verploegen

, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 2014; 74: 1214–1226.

19.

FDA grants accelerated approval to tisotumb vedotin-tftv for recurrent or metastatic cervical cancer. U.S. Food and Drug administration 2021. (accessed on November 21, 2021).

20.

TIVDAK (tisotumab vedotin-tftv) [package insert]. Bothell, WA: Seagen Inc.; 2021.

21.

Theunissen

Cai

Bhatti

, et al. Treating tissue factor-positive cancers with antibody-drug conjugates that do not affect blood clotting. Mol Cancer Ther 2018; 17: 2412–2426.

22.

Eisenreich

Bolbrinker

Leppert

. Tissue factor: a conventional or alternative target in cancer therapy. Clin Chem 2016; 62: 563–570.

23.

Hou

. Effect of tissue factor knockdown on the growth, invasion, chemoresistance and apoptosis of human gastric cancer cells. Exp Ther Med 2014; 7: 1376–1382.

24.

Rickles

Shoji

Abe

. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 2001; 73: 145–150.

25.

Zhao

Cheng

Gou

, et al. Expression of tissue factor in human cervical carcinoma tissue. Exp Ther Med 2018; 16: 4075–4081.

26.

Markham

. Tisotumab vedotin: first approval. Drugs 2021; 81: 2141–2147.

27.

Tisotumab vedotin. Seagen. https://www.seagen.com/science/pipeline/tisotumab-vedotin 2021. (accessed on November 21, 2021).

28.

Zhang

, et al. Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human phase 1 studies. MABS 2019; 12: e1699768

29.

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies (innovaTV 206). First posted on 12 April 2019. https://clinicaltrials.gov/ct2/show/NCT03913741?cond=tisotumab+vedotin&draw=2&rank=1 (accessed on 6 April 2022).

30.

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208). First posted on 4 September 2018. https://clinicaltrials.gov/ct2/show/NCT03657043?cond=tisotumab+vedotin&draw=2&rank=2 (accessed 6 April 2022).

31.

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301). First posted on 6 January 2021. https://clinicaltrials.gov/ct2/show/NCT04697628?cond=tisotumab+vedotin&draw=2&rank=3 (accessed on 6 April 2022).

32.

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. First posted on 10 August 2017. https://clinicaltrials.gov/ct2/show/NCT03245736?cond=tisotumab+vedotin&draw=2&rank=4 (accessed on 6 April 2022).

33.

A Trial of Tisotumab Vedotin in Cervical Cancer. First posted on 19 February 2018. https://clinicaltrials.gov/ct2/show/NCT03438396?cond=tisotumab+vedotin&draw=2&rank=5 (accessed on 6 April 2022).

34.

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (innovaTV 207). First posted on 2 April 2018. https://clinicaltrials.gov/ct2/show/NCT03485209?cond=tisotumab+vedotin&draw=2&rank=6 (accessed on 6 April 2022).

35.

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors. First posted on 16 September 2015. https://clinicaltrials.gov/ct2/show/NCT02552121?cond=tisotumab+vedotin&draw=2&rank=7 (accessed on 6 April 2022).

36.

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors. First posted on 5 December 2013. https://clinicaltrials.gov/ct2/show/NCT02001623?cond=tisotumab+vedotin&draw=2&rank=8 (accessed on 6 April 2022).

37.

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer. First posted on 24 December 2018. https://clinicaltrials.gov/ct2/show/NCT03786081?cond=tisotumab+vedotin&draw=2&rank=9 (accessed on 6 April 2022).

38.

Kim

Ursell

Coleman

, et al. Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol 2022;165(2): 385–392.

39.

Blenrep (belantamab mafodotin-blmf) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2022.

40.

Hong

Concin

Vergote

, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res 2020; 26: 1220–1228.

41.

TIVDAK. RED BOOK online. IBM Micromedex (accessed on November 24, 2021).

42.

In it with you – the whole way. Seagen Secure Patient Assistance Program. 2022. https://www.seagensecure.com/patient/tivdak (accessed on November 26, 2021).

43.

National Comprehensive Cancer Network. Antiemesis (Version 2.2022). 23 March 2022. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf (accessed on May 1, 2022).

44.

Santin

Sill

McMeekin

, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2011; 122: 495–500.

45.

Schilder

Blessing

Cohn

. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Gynecol Oncol 2005; 96: 103–107.

46.

Burotto

Edgerly

Poruchynsky

, et al. Phase II clinical trial of ixabepilone in metastatic cervical carcinoma. Oncologist 2015; 20: 725–726.

47.

Coronel

Cetina

Candelaria

, et al. Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. Med Oncol 2009; 26: 210–214.

48.

Rose

Blessing

Lele

, et al. Evaluation of pegylated liposomal doxorubicin (doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Gynecol Oncol 2006; 102: 210–213.